AbbVie Reports First-Quarter 2023 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
AbbVie (ABBV) shares slide despite revenue beat
April 27, 2023 8:55 AM EDTAbbVie (NYSE: ABBV) shares are tumbling premarket, currently down over 6% after the company reported its first-quarter earnings, which saw it report in-line profits and a revenue beat but miss sales estimates for some of its major drugs.
The company reported Q1 EPS of... More
AbbVie (ABBV) Reports In-Line Q1 EPS, Offers Guidance
April 27, 2023 7:34 AM EDTAbbVie (NYSE: ABBV) reported Q1 EPS of $2.46, in-line with the analyst estimate of $2.46. Revenue for the quarter came in at $12.23 billion versus the consensus estimate of $12.18 billion.
GUIDANCE:
AbbVie sees FY2023 EPS of $10.72-$11.12, versus the consensus of $10.94.
For earnings history and earnings-related data on AbbVie (ABBV) click here.
... More